ArticleFrontiers in pharmacology2024

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects.

Yue Fei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.